[New progresses of glaucoma research in China and abroad].

Zhonghua Yan Ke Za Zhi

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China.

Published: October 2010

Great progresses have recently been made in glaucoma fields, including basic research and clinical management. This review covers major areas in the study of glaucoma, including epidemiology, pathogenesis, integrated imaging technology, medicine, laser and surgical therapy of glaucoma, as well as the new trends of development. This paper provides the future direction in the research of glaucoma.

Download full-text PDF

Source

Publication Analysis

Top Keywords

progresses glaucoma
8
glaucoma
5
[new progresses
4
glaucoma china
4
china abroad]
4
abroad] great
4
great progresses
4
glaucoma fields
4
fields including
4
including basic
4

Similar Publications

Purpose: To investigate the effect of average intraocular pressure (IOP) on the true rate of glaucoma progression (RoP) in the United Kingdom Glaucoma Treatment Study (UKGTS).

Methods: UKGTS participants were randomized to placebo or Latanoprost drops and monitored for up to two years with visual field tests (VF, 24-2 SITA standard), IOP measurements, and optic nerve imaging. We included eyes with at least three structural or functional assessments (VF with <15% false-positive errors).

View Article and Find Full Text PDF

Background: The present study aims to identify the relationship between longitudinal changes in corneal hysteresis (CH) and progressive retinal nerve fibre layer (RNFL) thinning in a cohort of medically controlled, early-to-moderate open-angle glaucoma (OAG) patients with a history of laser refractive surgery (LRS).

Methods: A total of 123 consecutive eyes with a diagnosis of medically controlled (peak intraocular pressure (IOP)<18 mm Hg), early-to-moderate OAG with a history of LRS underwent measurements of CH, corneal-compensated intraocular pressure (IOPcc) and RNFL thicknesses every 6 months. Linear models were used to investigate the relationship between CH change and RNFL thickness change over time.

View Article and Find Full Text PDF

Treatment modalities and trends for hospitalized patients with neovascular glaucoma: A retrospective study of 10 years.

Asia Pac J Ophthalmol (Phila)

January 2025

State Key Laboratory of Ophthalmology, Guangzhou, China; Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China; Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China. Electronic address:

To analyze the treatment modalities and trends for neovascular glaucoma (NVG) over the past 10 years, we conducted a retrospective analysis at Zhongshan Ophthalmic Center on 1331 NVG inpatients who received 1459 treatments for 1383 eyes between January 1, 2012, and December 31, 2021. Over time, we observed a progressive annual increase in both the number of patients and the volume of surgeries for NVG, with an annual percentage change (APC) of 10.23% (95% confidence interval [CI]: 5.

View Article and Find Full Text PDF

Purpose: Genome-wide association studies (GWAS) have identified multiple genetic loci associated with primary open-angle glaucoma (POAG). However, the mechanisms by which these loci contribute to POAG progression remain unclear. This study aimed to identify potential causative genes involved in the development of POAG.

View Article and Find Full Text PDF

Objective: To report an unusual manifestation of normal tension glaucoma(NTG) in a young female as presenting feature of Takayasu arteritis (TA).

Methods: We present a case of a 24-year-old woman who was initially diagnosed with NTG, with characteristic optic disc and retinal nerve fiber layer (RNFL) changes, and corresponding visual field defects. Further evaluation with CT angiography revealed that the patient had newly diagnosed TA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!